DE69903750D1 - Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten - Google Patents

Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten

Info

Publication number
DE69903750D1
DE69903750D1 DE69903750T DE69903750T DE69903750D1 DE 69903750 D1 DE69903750 D1 DE 69903750D1 DE 69903750 T DE69903750 T DE 69903750T DE 69903750 T DE69903750 T DE 69903750T DE 69903750 D1 DE69903750 D1 DE 69903750D1
Authority
DE
Germany
Prior art keywords
long
chain
deoxynojirimycin
medicine
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69903750T
Other languages
English (en)
Other versions
DE69903750T2 (de
Inventor
S Jacob
Frances M Platt
Terry D Butters
Raymond A Dwek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Nutrasweet Co
Original Assignee
University of Oxford
Nutrasweet Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, Nutrasweet Co filed Critical University of Oxford
Application granted granted Critical
Publication of DE69903750D1 publication Critical patent/DE69903750D1/de
Publication of DE69903750T2 publication Critical patent/DE69903750T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69903750T 1998-12-10 1999-12-08 Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten Expired - Fee Related DE69903750T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11168398P 1998-12-10 1998-12-10
PCT/US1999/027918 WO2000033843A1 (en) 1998-12-10 1999-12-08 Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases

Publications (2)

Publication Number Publication Date
DE69903750D1 true DE69903750D1 (de) 2002-12-05
DE69903750T2 DE69903750T2 (de) 2003-06-12

Family

ID=22339901

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69903750T Expired - Fee Related DE69903750T2 (de) 1998-12-10 1999-12-08 Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten

Country Status (11)

Country Link
US (1) US6610703B1 (de)
EP (1) EP1137416B1 (de)
JP (1) JP2002531505A (de)
AT (1) ATE226821T1 (de)
AU (1) AU2347500A (de)
CA (1) CA2352544C (de)
DE (1) DE69903750T2 (de)
DK (1) DK1137416T3 (de)
ES (1) ES2190674T3 (de)
PT (1) PT1137416E (de)
WO (1) WO2000033843A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2393919T3 (es) 2002-07-17 2013-01-02 Actelion Pharmaceuticals Ltd. Derivados de PIPERIDINETRIOL como inhibidores de GLUCOSILCERAMIDA SINTASA
US7985760B2 (en) 2002-07-17 2011-07-26 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
SG184721A1 (en) * 2007-10-05 2012-10-30 Genzyme Corp Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) * 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010039256A1 (en) 2008-10-03 2010-04-08 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
ES2735023T3 (es) 2008-12-16 2019-12-13 Genzyme Corp Intermedios sintéticos para preparar conjugados de oligosacáridos-proteínas
KR101755133B1 (ko) * 2009-02-23 2017-07-06 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 바이러스성 질환을 치료하는 방법
KR20170117614A (ko) * 2009-02-24 2017-10-23 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
US8426445B2 (en) 2009-06-12 2013-04-23 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
KR20120081990A (ko) * 2009-09-04 2012-07-20 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 이미노당 및 필로바이러스 질환의 치료 방법
JP5653438B2 (ja) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
KR101459530B1 (ko) * 2009-09-04 2014-11-07 유나이티드 세러퓨틱스 코오포레이션 폭스바이러스 감염의 치료 방법
PT3133070T (pt) 2009-11-27 2019-11-11 Genzyme Corp Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars
US20160075651A1 (en) * 2013-05-02 2016-03-17 Unither Virology, Llc Glycolipid inhibition using iminosugars
JP6749923B2 (ja) 2015-02-02 2020-09-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン グルコシルセラミドシンターゼ阻害剤及びそれを使用した治療方法
EP3318277A1 (de) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitoren der glucosylceramidsynthase zur behandlung von motoneuronerkrankungen
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
EP4142878B1 (de) 2020-04-28 2024-06-26 The Regents of The University of Michigan Pyridinhemmer der glucosylceramidsynthase und therapeutische verfahren damit
KR20240061713A (ko) * 2022-11-01 2024-05-08 차의과학대학교 산학협력단 N-노닐데옥시노지리마이신을 포함하는 피부 가려움증의 억제, 경감, 개선, 또는 치료를 위한 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3507019A1 (de) * 1985-02-28 1986-08-28 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
AU732552B2 (en) 1996-07-15 2001-04-26 Genzyme Corporation Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
CA2252238A1 (en) 1997-10-31 1999-04-30 Sun Microsystems, Inc. Method and apparatus for sharing a time quantum

Also Published As

Publication number Publication date
AU2347500A (en) 2000-06-26
EP1137416A1 (de) 2001-10-04
JP2002531505A (ja) 2002-09-24
ES2190674T3 (es) 2003-08-01
DE69903750T2 (de) 2003-06-12
EP1137416B1 (de) 2002-10-30
DK1137416T3 (da) 2003-03-03
PT1137416E (pt) 2003-01-31
CA2352544C (en) 2007-11-13
CA2352544A1 (en) 2000-06-15
WO2000033843A1 (en) 2000-06-15
ATE226821T1 (de) 2002-11-15
US6610703B1 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
DE60001745D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
DE69824421D1 (de) Verfahren zur behandlung von zns-beteiligten lysosmalen speicherkrankheiten
ATE111733T1 (de) Verwendung von nikotin zur herstellung eines kit zur behandlung von krankheitszuständen, die auf eine nikotinbehandlung ansprechen.
ATE205389T1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE189601T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE199642T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung des knorpelabbaus
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
ATE220065T1 (de) Benzopyranderivate und ihre verwendung zur behandlung von herzkrankheiten
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee